Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Patients With IDH1 Positive Recurrent Grade II Glioma Enrolled in a Safety and Immunogenicity Study of Tumor-Specific Peptide Vaccine

NCT02193347 is registered in ClinicalTrials.gov with Katy Peters, MD, PhD as lead sponsor.

NCT NCT02193347
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02193347 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Patients With IDH1 Positive Recurrent Grade II Glioma Enrolled in a Safety and Immunogenicity Study of Tumor-Specific Peptide Vaccine
Lead sponsor
Katy Peters, MD, PhD
Phase
Phase 1
Overall status
Completed
Start date
January 28, 2016
Completion date
February 3, 2020
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brain cancer, brain neoplasm, primary, brain neoplasms, recurrent, brain tumor, cancer of the brain